Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–33 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Evaluation of Intranasal Nalmefene

NCT04828005
Conditions
Pharmacodynamic
Interventions
Nalmefene hydrochloride, Naloxone hydrochloride
Drug
Lead sponsor
Opiant Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Opioid Overdose
Interventions
16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray
Combination Product
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Caregiver, Patient
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Opioid Use Disorder, Cannabis Use
Interventions
Cannabis, Placebo Cannabis, Intranasal Opioid Agonist, Oral Opioid Agonist
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473
Conditions
Heroin Dependence
Interventions
Intranasal challenge drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH), Headache
Interventions
Lidocaine (drug), Tx 360
Drug · Device
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, Oxytocin nasal spray, Placebo Oxycodone, Placebo oxytocin, OxyCODONE 2.5 mg Oral Tablet
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, OxyCODONE 2.5 mg Oral Tablet, Placebo oxyCODONE Oral Tablet, Oxytocin Nasal Spray (48 IU), Placebo Oxytocin Nasal Spray
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida